Recommended Topic Related To:

Oncaspar

"The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States.

Biological products are generally derived from a living organism. They can come from many sources, in"...

Oncaspar




PATIENT INFORMATION

Serious Allergic Reactions

Inform patients of the possibility of serious allergic reactions, including anaphylaxis, and to seek immediate medical care for any swellings or difficulty breathing.

Thrombosis

Inform patients to seek immediate medical attention for severe headache, arm or leg swelling, acute shortness of breath, or chest pain.

Pancreatitis

Advise patients to seek immediate medical attention for severe abdominal pain.

Glucose Intolerance

Advise patients to immediately report excessive thirst or increase in the volume or frequency of urination.

Last reviewed on RxList: 5/2/2014
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Cancer

Get the latest treatment options.